Compare LAZ & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAZ | ACAD |
|---|---|---|
| Founded | 1848 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2004 | 2000 |
| Metric | LAZ | ACAD |
|---|---|---|
| Price | $47.42 | $22.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $52.75 | $30.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | 2.17 | ★ 2.30 |
| Revenue | ★ $3,186,466,000.00 | $726,437,000.00 |
| Revenue This Year | $13.36 | $18.80 |
| Revenue Next Year | $13.72 | $11.70 |
| P/E Ratio | $21.92 | ★ $9.64 |
| Revenue Growth | 1.48 | ★ 40.45 |
| 52 Week Low | $38.67 | $14.45 |
| 52 Week High | $58.75 | $28.35 |
| Indicator | LAZ | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 53.59 |
| Support Level | $38.84 | $20.80 |
| Resistance Level | $52.19 | $22.97 |
| Average True Range (ATR) | 2.19 | 0.60 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 38.25 | 82.79 |
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.